Retevmo (Selpercatinib)

Brand Name

Retevmo

Generic Name

Selpercatinib

View Brand Information

FDA approval date: May 08, 2020

Classification: Kinase Inhibitor

Form: Tablet, Capsule

What is Retevmo (Selpercatinib)?

RETEVMO ® is a kinase inhibitor indicated for the treatment of: Adult patients with locally advanced or metastatic non-small cell lung cancer with a rearranged during transfection gene fusion, as detected by an FDA-approved test.

Approved To Treat

Top Global Experts

Save this treatment for later

Not sure about your diagnosis?

Check Your Symptoms

Related Clinical Trials

Selpercatinib to Enhance RAI Avidity in Children, Adolescents, and Young Adults With Newly Diagnosed Differentiated Thyroid Cancers Harboring RET Fusions

Enrollment Status: Recruiting

Publish Date: April 15, 2026

Intervention Type: Radiation, Drug

Study Phase: Phase 2

Summary: Papillary thyroid cancer (PTC) is the most common form of differentiated thyroid cancer (DTC). The traditional first line treatment for patients with advanced DTC after surgical resection is radioactive iodine (RAI) therapy. However, less than a quarter of patients with lung metastases will achieve a complete response to RAI therapy, and this therapy carries the risk of pulmonary fibrosis and an i...

Biochemical, Radiological and Pathological Responses to Neoadjuvant Treatment in Locally Advanced Thyroid Cancer: A Multicenter Study

Enrollment Status: Recruiting

Publish Date: February 19, 2026

Intervention Type: Drug, Procedure

Summary: This multicenter observational study aims to evaluate the safety and efficacy of neoadjuvant therapy in patients with locally advanced thyroid cancer, focusing on imaging, biochemical, and pathological responses, as well as short-term surgical outcomes and long-term prognosis.

A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer

Enrollment Status: Recruiting

Publish Date: August 14, 2025

Intervention Type: Drug

Study Phase: Phase 4

Summary: This is a retrospective and prospective real-world clinical study of molecular typing in the treatment of advanced thyroid cancer. The retrospective study : Patients with advanced thyroid cancer who received precise treatment in the 24 participated hospitals from January 2020 to December 2023 were retrieved. The number of previous treatment lines was not limited. Patients who met the inclusion cri...

View All Clinical Trials

Related Latest Advances

Adjuvant selpercatinib shows benefit in patients with NSCLC.

Journal: Nature reviews. Clinical oncology

Published: June 11, 2026

Combination of Selpercatinib and Trametinib Overcomes Resistance to RET Inhibitors in RET-Mutant Medullary Thyroid Carcinoma.

Journal: JCO precision oncology

Published: June 08, 2026

RET Fusion-Positive Solid Tumor

Journal: Gan to kagaku ryoho. Cancer & chemotherapy

Published: June 04, 2026

View All Latest Advances

Brand Information

RETEVMO (selpercatinib)

1DOSAGE FORMS AND STRENGTHS

Capsules:

40 mg: gray opaque capsule imprinted with “Lilly”, “3977” and “40 mg” in black ink.
80 mg: blue opaque capsule imprinted with “Lilly”, “2980” and “80 mg” in black ink.

Tablets:

40 mg: light gray, film coated, round tablet debossed with “Ret 40” on one side and “5340” on the other side.
80 mg: dark red-purple, film coated, round tablet debossed with “Ret 80” on one side and “6082” on the other side.
120 mg: light purple, film coated, round tablet debossed with “Ret 120” on one side and “6120” on the other side.
160 mg: light pink, film coated, round tablet debossed with “Ret 160” on one side and “5562” on the other side.

2CONTRAINDICATIONS

None.

3ADVERSE REACTIONS

The following clinically significant adverse reactions are described elsewhere in the labeling:

Hepatotoxicity
Interstitial Lung Disease / Pneumonitis
Hypertension
QT Interval Prolongation
Hemorrhagic Events
Hypersensitivity
Tumor Lysis Syndrome
Risk of Impaired Wound Healing
Hypothyroidism
Slipped Capital Femoral Epiphysis/Slipped Upper Femoral Epiphysis in Adolescent Patients

3.1Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The safety population described in the WARNINGS and PRECAUTIONS and below reflects exposure to RETEVMO as a single agent administered at 160 mg orally twice daily evaluated in 857 patients with advanced solid tumors in LIBRETTO-001

3.2Postmarketing Experience

The following adverse reaction has been identified during post-approval use of RETEVMO. Because such reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Skin and subcutaneous tissue disorders: Stevens-Johnson Syndrome

4DESCRIPTION

RETEVMO contains selpercatinib, a kinase inhibitor. The molecular formula for selpercatinib is C

Selpercatinib is a white to light yellow powder that is slightly hygroscopic. The aqueous solubility of selpercatinib is pH dependent, from sparingly soluble at low pH to practically insoluble at neutral pH.

RETEVMO capsules contain either 40 mg or 80 mg of selpercatinib in hard gelatin capsules for oral use. Each capsule contains inactive ingredients of colloidal silicon dioxide and microcrystalline cellulose. The 40 mg capsule shell is composed of gelatin, titanium dioxide, ferric oxide black and black ink. The 80 mg capsule shell is composed of gelatin, titanium dioxide, FD&C blue #1 and black ink. The black ink is composed of shellac, potassium hydroxide and ferric oxide black.

RETEVMO tablets contain 40 mg, 80 mg, 120 mg, or 160 mg of selpercatinib as film coated, debossed tablets for oral use. Each tablet contains inactive ingredients of croscarmellose sodium, hydroxypropyl cellulose, mannitol, microcrystalline cellulose, and sodium stearyl fumarate. The tablet film coating material contains polyvinyl alcohol, titanium dioxide, polyethylene glycol, and talc. Additionally, the film coating of the 40 mg, 80 mg, and 120 mg tablets contains ferrosoferric oxide and the film coating of the 80 mg, 120 mg, and 160 mg tablets contain ferric oxide.

5PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling (Patient Information).